Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Paclitaxel + VB-111|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|VB-111||Ofranergene Obadenovec||VB111||Ofranergene Obadenovec (VB-111) is an engineered adenovirus that expresses Fas-c specifically within endothelial cells, resulting in endothelial cell death and decreased tumor blood supply, and potentially leading to tumor cell death (PMID: 22701765)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||Paclitaxel + VB-111||Case Reports/Case Series||Actionable||In a clinical study, VB-111 in combination with Taxol (paclitaxel) resulted in increased tumor lymphocyte infiltration and tumor necrosis in biopsies obtained from 3 patients with ovarian cancer (AACR Annual Meeting 2019, Abstract 4979).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03398655||Phase III||Paclitaxel Paclitaxel + VB-111||A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL)||Recruiting|